Armata Pharmaceuticals, Inc. — Director's Dealing 2016

Dec 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AmpliPhi Biosciences Corp (APHB)
CIK: 0000921114
Period of Report: 2016-12-27

Reporting Person: KIRK RANDAL J (10% Owner)
Reporting Person: INTREXON CORP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-27	Common Stock	S	26308	$.51	Disposed	802263	Indirect
2016-12-28	Common Stock	S	44170	$.47	Disposed	758093	Indirect
2016-12-29	Common Stock	S	21923	$.45	Disposed	736170	Indirect
2016-12-27	Common Stock	S	24092	$.51	Disposed	734696	Indirect
2016-12-28	Common Stock	S	40450	$.47	Disposed	694246	Indirect
2016-12-29	Common Stock	S	20077	$.45	Disposed	674169	Indirect

Footnotes

F1: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis.

F2: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.